Seeking Alpha

Appearing a bit late to the party, Jefferies raises its price target on Regeneron...

Appearing a bit late to the party, Jefferies raises its price target on Regeneron Pharmaceuticals (REGN -1.3%) to $247 from $179 citing the company's top line, EYLEA sales-driven earnings beat. Jefferies is responding to REGN's hike of FY13 EYLEA sales estimates — the company pointed to a strong ex-U.S. rollout. Q1 sales of the macular degeneration injection were $314M compared to $124M in Q1 2012.
Comments (1)
  • fxdudeinmia
    , contributor
    Comments (491) | Send Message
     
    Heckuva job, Brownie!! Where did Jefferies find such a terrific analyst ?
    6 May 2013, 03:32 PM Reply Like
DJIA (DIA) S&P 500 (SPY)